Reassessing target antigens for adoptive T-cell therapy. - Wikidata - awgldk - TriplyDB

Reassessing target antigens for adoptive T-cell therapy.

Reassessing target antigens for adoptive T-cell therapy.

http://www.wikidata.org/entity/Q34789569

about

CAR T cells for solid tumors: armed and ready to go?Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?T-cell receptor gene therapy--ready to go viral?Smart CARs engineered for cancer immunotherapy Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors Improving the safety of cell therapy with the TK-suicide gene Linking T-cell receptor sequence to functional phenotype at the single-cell level.Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions.Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6 Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy Driving CAR-based T-cell therapy to success.Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.Targeting cancer-specific mutations by T cell receptor gene therapy.Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.Glioblastoma antigen discovery--foundations for immunotherapy.Synthetic biology in cell-based cancer immunotherapy.Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Harnessing the immune system for the treatment of melanoma: current status and future prospects.Chimeric antigen receptors: driving immunology towards synthetic biology.Differential ion mobility spectrometry coupled to tandem mass spectrometry enables targeted leukemia antigen detection.Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Immune and viral therapies for malignant primary brain tumors.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Therapeutic T cell engineering.Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

P2860

Q26825489-FCDB13CE-C6A7-4AF3-BFD5-099391FC972E Q28078539-7AA5B7C4-3F80-4117-98EA-74B1BB2BE368 Q28081611-DE9208F6-5141-42F1-B7D0-2F3895799400 Q28087236-11F54558-51C4-4A05-B8EA-724B91849201 Q33594333-73B55695-5A73-42B9-A48C-B8D5C7550ADA Q34309388-E6774C8A-D16A-4860-A724-7FD86BA4754C Q34477411-D768D6BF-E9C2-4C56-B89C-564E38F816E1 Q35111823-6B6451E6-A040-4496-9A4B-A7D01AADC497 Q35532355-B9114FA1-C74D-4A3C-AA98-EE73AAD16B8C Q35563824-AC067C1E-0D50-477E-AD9E-19EC05C644A3 Q36028047-171B6000-4C01-4FAA-B5E3-A73ECE397E06 Q36083324-62F94A75-3DCD-4A58-A9F9-6AFE39C3ACF7 Q36154471-70723E17-9B69-4FF8-ABFA-6182EBFA8A67 Q36928580-14C78F90-704A-4844-88F0-020B55177A5D Q36957716-EDAADDDD-7B20-4D42-8BB8-7C5CB89A116B Q37652790-2E32C442-E0A5-4F23-A3E1-B80510AF418B Q37715684-F5AF8771-7B5A-4EE9-B022-9581C866C70F Q38195656-50AA1FD6-A198-45AE-9DDA-3EEC4CDEBBD6 Q38366556-2573117F-5D02-4E17-BE2C-8B40823A40BE Q38390185-43053805-9AB3-4D33-9D56-54B406BDD642 Q38445486-F39FEF6A-9B20-4065-AAF5-8A0C8FF6AFB8 Q38516823-1EB87DA8-0025-4331-8645-76DFEE321EEF Q38531361-D8D93275-09F3-497F-B108-1C4FC4F47C22 Q38683157-637574A9-DC9C-427D-8DE6-F953ACF420BA Q38786626-FF286EF1-F95D-464C-A55F-B8A7B1354A8C Q38806243-5C889FE8-D5FF-498D-9B3D-0561B98196D3 Q38884383-3168CCF2-6AC0-4928-82E1-F17C68087AA3 Q38960204-DABB794E-35F9-4DE1-8C05-7E7651112251 Q39037485-A918B452-67A9-4BA9-8BFF-8AB78F69AD03 Q39057617-82C1B687-60B6-46B6-8777-155990C4C345 Q39168899-1640A641-D443-46C4-9FD1-5E251C682BC9 Q39246685-B6059263-9ABD-4084-A1B3-6EF49EBF1369 Q39272183-28521227-B096-4F21-B7B1-4D91387F4650 Q40096913-674E3F7A-27E4-4299-AF5D-0DEF3BA8A00E Q40199809-404647CD-1239-41FD-8CA7-CDD4B739CA6E Q41257879-EBE0FD94-F6DB-4A0C-804B-FD5A263E1AE2 Q41592700-9E2568AA-CB3E-4B92-8F0E-44F1294F827B Q41625041-E88E5E20-4214-4662-8B4B-A73F911C0C96 Q41660817-0B7AECED-5E93-4B5B-A4D7-6017E63681C0 Q41722598-A79C4B37-E7F5-4DE1-99AD-0C298BDF89E6

P2860

Reassessing target antigens for adoptive T-cell therapy.

http://www.wikidata.org/entity/Q34789569

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Reassessing target antigens for adoptive T-cell therapy.

@ast

Reassessing target antigens for adoptive T-cell therapy.

@en

Reassessing target antigens for adoptive T-cell therapy.

@nl

type

label

Reassessing target antigens for adoptive T-cell therapy.

@ast

Reassessing target antigens for adoptive T-cell therapy.

@en

Reassessing target antigens for adoptive T-cell therapy.

@nl

prefLabel

Reassessing target antigens for adoptive T-cell therapy.

@ast

Reassessing target antigens for adoptive T-cell therapy.

@en

Reassessing target antigens for adoptive T-cell therapy.

@nl

P1433

Q34789569-BA550F36-D739-4941-A592-E7CA91FC9759

P1476

Q34789569-EAD4CD84-D68F-4BD9-8633-3B4E25E6C2D5

P2093

Q34789569-FB2ABD41-E990-4B90-ADAF-A4D785B35598

P2860

Q34789569-0791275E-CB82-46FB-83CB-293F3B17F5A0

Q34789569-07A63DBE-5F7E-48E7-B620-A0BEC466C5A9

Q34789569-0AA73EC7-1A0D-4167-9FF1-8911235C33DD

Q34789569-0AE8B6EB-C094-4981-9DA2-FDC19866D12B

Q34789569-0EDB929D-1EC0-4927-8FB1-52A5E293BE30

Q34789569-10281ACC-0A29-461E-9D8A-EE630F0EA842

Q34789569-11D35A0A-B40A-4BA9-B0BE-DF8F350C9836

Q34789569-1CA93280-A6A8-4669-BDDB-61E1758A31C3

Q34789569-1F890551-3155-42C5-8A67-EFD9B7646025

Q34789569-21506C4D-4274-4CF7-AC42-DB4FBDB61689

P2888

Q34789569-C2CD84C9-3A09-4A5E-A340-3F651850C9DB

P304

Q34789569-FE4B4FE5-F7F3-4880-95F5-E3EBF53A784F

P31

Q34789569-BAB7525D-AB4E-49F1-9C36-8F675447CCCA

Q34789569-F36F070A-E948-44E1-A0AD-1D0C5EA09181

P356

Q34789569-9649E7F6-C6E4-4230-9B33-C229DC1242F8

P433

Q34789569-7479C1F5-EBCD-4843-9B40-71EA3D81130E

P478

Q34789569-924921D8-4D14-483E-9318-0B2EBD5C8EEA

P50

Q34789569-7FFEB2B9-29D4-4BD9-A399-10963BAB64B1

P577

Q34789569-2F5E5B41-8EA2-4F77-80CF-3DB8AFEC4E46

Q34789569-EE633878-C966-4A72-AA8E-47FC1251F62B

P5875

Q34789569-1B041573-C8E9-471B-AA77-EEA3A7A4D311

P6179

Q34789569-515B2102-DCFE-48F5-AAAB-D1A9AAA56A26

P698

Q34789569-8F7BF767-6E8E-4406-AA0C-EC6E912BD14D

P921

Q34789569-CFF6DF2B-2D50-4065-9E00-6CF23C037BCB

P932

Q34789569-CB2DD666-1506-485C-A017-A26F0954D756

P356

P1433

Nature Biotechnology

P1476

Reassessing target antigens for adoptive T-cell therapy.

@en

P2093

Christian S Hinrichs

http://www.w3.org/2001/XMLSchema#string

P2860

BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources.

Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library

Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer

Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Cancer immunotherapy: moving beyond current vaccines

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

P2888

P304

999-1008

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.2725

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2013-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258061317

http://www.w3.org/2001/XMLSchema#string

P6179

1047644498

http://www.w3.org/2001/XMLSchema#string

P698

24142051

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

4280065

http://www.w3.org/2001/XMLSchema#string